Role of T Cell and Vascular NADPH Oxidases in Angiotensin II Induced Hypertension

T 细胞和血管 NADPH 氧化酶在血管紧张素 II 诱导的高血压中的作用

基本信息

  • 批准号:
    7486017
  • 负责人:
  • 金额:
    $ 5.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hypertension (HTN) is the number one attributable risk factor for death worldwide leading to increased morbidity and mortality from ischemic heart disease, heart failure, stroke, and chronic kidney disease. Reactive oxygen species (ROS) produced by the NADPH family of oxidases contributes to the pathophysiology of HTN. However, a key unresolved issue is which cell type is critical in the regulation of blood pressure (BP) and what is the relevant enzymatic/signaling pathways involved. Preliminary data from our lab suggests that T cells via a T cell NADPH oxidase are essential for HTN induced by angiotensin II (Ang II). We propose a model in which Ang II acts directly on T cells and has central effects which lead to T cell activation and that activated T cells then act on vessel walls and the kidney via infiltration and cytokine release to stimulate local NADPH oxidases which in turn promote HTN. In this proposal, we will investigate the role of the T cell NADPH oxidase vs vascular NADPH oxidases in Ang II induced HTN by addressing the following specific aims. Specific Aim 1. Define the role of the T cell NADPH oxidase in Ang II induced HTN by targeted knockout of the T cell p22phox. Using transgenic mouse models, we will create mice in which p22phox, a critical component of most types of NADPH oxidase, is deleted in T cells only. We will then determine the effect of Ang II on BP response, aortic superoxide production, and vascular reactivity. Specific Aim 2. Further elucidate the mechanism of T cell mediated HTN by determining the effect of the T cell NADPH oxidase on T cell infiltration into the vessel wall. Preliminary data from our lab showed that Ang II markedly increased the number of T cells in the adventitia and periadventitial fat and that this increase was diminished in mice with defective NADPH oxidase in all cells. In this aim, we will use mice with targeted deletion of p22phox in T cells only to determine the effect on T cell infiltration. Specific Aim 3. Define the role of the vascular smooth muscle cell (VSMC) NADPH oxidase vs the endothelial cell (EC) NADPH oxidase in Ang II induced HTN and T cell infiltration by conditional, targeted knockout of p22phox in VSMCs or ECs. The experiments described in this research proposal will further our understanding of the mechanisms by which ROS contribute to hypertension. High blood pressure is a common condition and major risk factor for heart disease, stroke, and kidney disease. The studies described in this proposal will further our understanding of the cell types and pathways involved in the development of high blood pressure and hopefully lead to better treatments for this condition.
描述(申请人提供):高血压(HTN)是全球头号可归因性死亡风险因素,导致缺血性心脏病、心力衰竭、中风和慢性肾脏疾病的发病率和死亡率增加。NADPH氧化酶家族产生的ROS参与HTN的病理生理过程。然而,一个关键的悬而未决的问题是,哪种细胞类型在调节血压(BP)中起关键作用,以及相关的酶/信号通路是什么。我们实验室的初步数据表明,在血管紧张素II(Ang II)诱导的HTN中,T细胞通过T细胞NADPH氧化酶是必不可少的。我们提出了一个模型,在这个模型中,Ang II直接作用于T细胞,并具有中枢作用,导致T细胞激活,然后激活的T细胞通过渗透和细胞因子释放作用于血管壁和肾脏,刺激局部NADPH氧化酶,进而促进HTN。在这项研究中,我们将探讨T细胞NADPH氧化酶和血管NADPH氧化酶在血管紧张素转换酶诱导的HTN中的作用。具体目的1.明确T细胞NADPH氧化酶在Ang II靶向敲除T细胞p22Phox诱导的HTN中的作用。使用转基因小鼠模型,我们将创造出只在T细胞中缺失p22Phox的小鼠,p22Phox是大多数类型NADPH氧化酶的关键成分。然后我们将确定血管紧张素转换酶II对血压反应、主动脉超氧化物生成和血管反应性的影响。具体目的2.通过检测T细胞NADPH氧化酶对T细胞进入血管壁的影响,进一步阐明T细胞介导HTN的机制。我们实验室的初步数据显示,Ang II显著增加外膜和外膜脂肪中的T细胞数量,这种增加在所有细胞中NADPH氧化酶缺陷的小鼠中都减弱。在这个目的中,我们将使用靶向缺失T细胞中的p22Phox的小鼠来确定其对T细胞渗透的影响。具体目的3.明确血管平滑肌细胞(VSMC)NADPH氧化酶和内皮细胞(EC)NADPH氧化酶在Ang II通过条件性靶向敲除VSMC或ECs中的p22Phox诱导HTN和T细胞浸润中的作用。这项研究计划中描述的实验将进一步加深我们对ROS促进高血压的机制的理解。高血压是一种常见疾病,也是心脏病、中风和肾脏疾病的主要危险因素。这项提案中描述的研究将进一步加深我们对高血压发生过程中所涉及的细胞类型和途径的了解,并有望导致对这种疾病的更好治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Meenakshi Swaminathan Madhur其他文献

Meenakshi Swaminathan Madhur的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Meenakshi Swaminathan Madhur', 18)}}的其他基金

Immune Modulation in Hypertension
高血压的免疫调节
  • 批准号:
    10521590
  • 财政年份:
    2022
  • 资助金额:
    $ 5.13万
  • 项目类别:
Immune Modulation in Hypertension
高血压的免疫调节
  • 批准号:
    10634746
  • 财政年份:
    2022
  • 资助金额:
    $ 5.13万
  • 项目类别:
Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic Targets
使用单细胞多重质谱流式细胞仪对人类高血压进行免疫表型分析,以确定新的治疗靶点
  • 批准号:
    10000699
  • 财政年份:
    2021
  • 资助金额:
    $ 5.13万
  • 项目类别:
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension
白细胞介素 17 亚型在高血压发病机制中的多种作用
  • 批准号:
    8617022
  • 财政年份:
    2014
  • 资助金额:
    $ 5.13万
  • 项目类别:
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension
白细胞介素 17 亚型在高血压发病机制中的多种作用
  • 批准号:
    9205258
  • 财政年份:
    2014
  • 资助金额:
    $ 5.13万
  • 项目类别:
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension
白细胞介素 17 亚型在高血压发病机制中的多种作用
  • 批准号:
    9275079
  • 财政年份:
    2014
  • 资助金额:
    $ 5.13万
  • 项目类别:
Role of T Cell and Vascular NADPH Oxidases in Angiotensin II Induced Hypertension
T 细胞和血管 NADPH 氧化酶在血管紧张素 II 诱导的高血压中的作用
  • 批准号:
    7693802
  • 财政年份:
    2008
  • 资助金额:
    $ 5.13万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 5.13万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 5.13万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 5.13万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 5.13万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 5.13万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 5.13万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 5.13万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 5.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了